Operating profit at 138.6 billion won, up 40.2% year-on-year
Net profit at 115.8 billion won, up 104.2%

Hanmi Science, the holding company of Hanmi Group, posted record-high results last year with sales of 1.3568 trillion won.

Hanmi Group promotional image. Hanmi Science

Hanmi Group promotional image. Hanmi Science

View original image

On February 5, Hanmi Science announced through a public filing that, on a consolidated and provisional basis for 2025, it achieved sales of 1.3568 trillion won, operating profit of 138.6 billion won, and net profit of 115.8 billion won. Sales increased by 5.7% year-on-year, while operating profit and net profit rose by 40.2% and 104.2%, respectively. Fourth-quarter sales came in at 343.9 billion won. During the same period, operating profit was 37.6 billion won and net profit was 31.1 billion won.


The company explained that improved performance in its own business divisions and an increase in equity-method gains from affiliates drove earnings growth. A reduction in one-off expenses also contributed to the expansion of operating profit.


Since transitioning to a professional management system last year, Hanmi Science has been performing the role of a control tower in charge of group-wide strategy formulation and resource allocation. At the same time, it has been increasing the share of its own businesses, including medical devices, consumer health, and pharmaceutical distribution.


Sales in the healthcare business rose 19.6% year-on-year to 151.9 billion won. Onlinepharm, the pharmaceutical distribution unit, recorded sales of 1.1367 trillion won, driven by higher sales of major over-the-counter medicines.


In the medical device segment, the adhesion barrier Gadix generated sales of 23.1 billion won, while the hemostatic agent Acticlot, supported by an expansion of reimbursement codes, posted 8.1 billion won in sales, up 77% from a year earlier.


The H&B business, which includes cosmetics and health functional foods, also showed growth. Sales of the cosmetics brand PRO-CALM were tallied at 12.1 billion won, up 75% year-on-year.



Hanmi Science CEO Kim Jaekyo said, "We are building a structure that delivers direct results across various businesses, including medical devices, consumer health, and pharmaceutical automation," adding, "We will strengthen our competitiveness by focusing on high-growth healthcare areas."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing